Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Real-world costs of autosomal dominant polycystic kidney disease in the Nordics
Quantify Res, Hantverkargatan 8, S-11221 Stockholm, Sweden..
Quantify Res, Hantverkargatan 8, S-11221 Stockholm, Sweden..
Quantify Res, Hantverkargatan 8, S-11221 Stockholm, Sweden..
Odense Univ Hosp, Dept Nephrol, Sdr Blvd 29, DK-5000 Odense C, Denmark..
Show others and affiliations
2017 (English)In: BMC Health Services Research, ISSN 1472-6963, E-ISSN 1472-6963, Vol. 17, 560Article in journal (Refereed) Published
Abstract [en]

Background: There is limited real-world data on the economic burden of patients with autosomal dominant polycystic kidney disease (ADPKD). The objective of this study was to estimate the annual direct and indirect costs of patients with ADPKD by severity of the disease: chronic kidney disease (CKD) stages 1-3; CKD stages 4-5; transplant recipients; and maintenance dialysis patients. Methods: A retrospective study of ADPKD patients was undertaken April-December 2014 in Denmark, Finland, Norway and Sweden. Data on medical resource utilisation were extracted from medical charts and patients were asked to complete a self-administered questionnaire. Results: A total of 266 patients were contacted, 243 (91%) of whom provided consent to participate in the study. Results showed that the economic burden of ADPKD was substantial at all levels of the disease. Lost wages due to reduced productivity were large in absolute terms across all disease strata. Mean total annual costs were highest in dialysis patients, driven by maintenance dialysis care, while the use of immunosuppressants was the main cost component for transplant care. Costs were twice as high in patients with CKD stages 4-5 compared to CKD stages 1-3. Conclusions: Costs associated with ADPKD are significant and the progression of the disease is associated with an increased frequency and intensity of medical resource utilisation. Interventions that can slow the progression of the disease have the potential to lead to substantial reductions in costs for the treatment of ADPKD.

Place, publisher, year, edition, pages
2017. Vol. 17, 560
Keyword [en]
Polycystic kidney diseases, ADPKD, Health Care Costs, Health Expenditures, Cost of Illness
National Category
Health Care Service and Management, Health Policy and Services and Health Economy
Identifiers
URN: urn:nbn:se:uu:diva-332655DOI: 10.1186/s12913-017-2513-8ISI: 000407824600001PubMedID: 28806944OAI: oai:DiVA.org:uu-332655DiVA: diva2:1156510
Available from: 2017-11-13 Created: 2017-11-13 Last updated: 2017-11-13Bibliographically approved

Open Access in DiVA

fulltext(430 kB)6 downloads
File information
File name FULLTEXT01.pdfFile size 430 kBChecksum SHA-512
dff7f757c4cc001d19494bbe6ea22be731d09ffa3713e1c037ac2882b645a38274e5d3e41f1290343efdfc9337a704cf7936786604770dd0f755825114bb302a
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Melin, Jan
By organisation
Renal Medicine
In the same journal
BMC Health Services Research
Health Care Service and Management, Health Policy and Services and Health Economy

Search outside of DiVA

GoogleGoogle Scholar
Total: 6 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 21 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf